November 12: Valuation of Innovative Drugs - In Person at ISPOR Europe 2023

November 12, 2023

Back to all short courses

Valuation of Innovative Drugs (in person)

Health Policy & Regulatory
4 Hours | Course runs 1 day

This short course is offered in-person at the ISPOR Europe 2023 conference. Separate registration is required. Visit the ISPOR Europe 2023 Program page to register and learn more.

Sunday, 12 November 2023 | Course runs 1 Day
13:00-17:00 Central European Time (CET) 


The value of medical innovation depends on the perspective. Registration authorities (EMA, FDA) mainly consider the clinical value of the medical innovation, whereas national health authorities take a broader perspective by including clinical, economic criteria, and potential other criteria like equity and social values. Value-based pricing is the most widely accepted approach in the pricing and reimbursement process in Europe, which varies from the narrow concept based on the incremental cost-effectiveness ratio (ICER) threshold to broader approaches. Value-based pricing determines the maximum price from the national payer perspective. This price should exceed the minimum price for the investor acting in the international financial market, which is based on economic valuation theory. Finally, there are other stakeholders, eg, patients, physicians’ healthcare insurers, employers, with their specific assessment of the value of medical innovation varying from, respectively, quality of life, effectiveness, budget impact, and costs of lost productivity. This course offers an overview of the perspectives of the relevant stakeholders and their respective data requirements for value assessment of innovative drugs. The course will then describe in-depth description of the various value-based pricing methods, eg, ICER, multicriteria decision analysis (MCDA), comparative effectiveness research (CER), and relative effectiveness (RE). We include examples of orphan drugs and ATMPs which are most striking to illustrate the concepts, but we also include value assessment for more traditional innovative drugs in broad indications. Familiarity with health economic evaluation is desirable, but the course assumes little or no familiarity with economic valuation theory.

Registrants receive a digital course book. Copyright, Trademark and Confidentiality Policies apply.


Louis P. Garrison, Jr, PhD
Professor Emeritus
The Comparative Health Outcomes, Policy, and Economics Institute
Department of Pharmacy, University of Washington
Seattle, WA, USA

Marlene Gyldmark, MPhil
External Lecturer Copenhagen University
Copenhagen, Denmark and
Head HEOR & Epidemiology
Idorsia Pharmaceuticals
Allschwill, Switzerland

Afschin Gandjour, MD, PhD, MA
Professor of Health Management
Frankfurt School of Finance & Management
Frankfurt, Germany

Fred Sorenson, MSc
Director, Global Market Access & Support
Basel, Switzerland


Mark Nuijten, PhD, MD, MBA
Visiting Professor
Clinical and Economic Valuation of Medical Innovation
Ben Gurion University
Be'er Sheva, Israel and
Amsterdam, North Holland, Netherlands


Basic Schedule:

4 Hours | Course runs 1 Day

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now